Pancreatic cancer diagnostics company Immunovia (STO:IMMNOV) announced on Friday that it has filed a provisional patent application in the United States to protect its next-generation test for detecting stage 1 and 2 pancreatic cancer.

The patent application covers the combination of five specific biomarkers used in the test, as well as the method for combining these biomarkers to generate a positive or negative test result.

In the coming months Immunovia plans to submit additional clinical data to strengthen its patent application. It will also file a single PCT (Patent Cooperation Treaty) application within the next year to seek global patent protection.

Immunovia aims to launch the new test in the US in 2025, following a large clinical validation study in the fourth quarter of 2024.